CCL2

CCL2

CCL2 Molekülinformation

Molecule Name
C-C motif chemokine 2
Molekülalias
CCL2,C-C motif chemokine 2,MCP-1,MCAF
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
MCP1,HC11,Monocyte chemotactic protein 1,Monocyte chemoattractant protein 1,CCL2,C-C Motif Chemokine Ligand 2,Monocyte Chemotactic And Activating Factor,Monocyte Secretory Protein JE,Small Inducible Cytokine A2 (Monocyte Chemotactic Protein 1, Homologous To Mouse Sig-Je),Small Inducible Cytokine Subfamily A (Cys-Cys), Member 2,Monocyte Chemoattractant Protein-1,Chemokine (C-C Motif) Ligand 2,Small-Inducible Cytokine A2,SCYA2,MCP-1,MCAF,Monocyte Chemotactic Protein 1, Homologous To Mouse Sig-Je,C-C Motif Chemokine 2,HSMCR30,GDCF-2,SMC-CF,Chemokine CCL2,MGC9434
Molekülhintergrund
Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2, a member of the CC subfamily, is characterized by two adjacent cysteine residues. CCL2 displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. Elevated expression of the encoded protein is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

CCL2 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
AFX-5931AFX-5931Phase 2 ClinicalAfecta Pharmaceuticals Inc
Eczema
Details
MW-151MW01-9-034WH; MW-151; MW01-2-151SRMPhase 1 ClinicalUniversity Of Kentucky
Drug-Related Side Effects and Adverse Reactions; Poisoning
Details
64CU-DOTA-ECL1iPhase 1 ClinicalWashington University School Of Medicine
Arteriosclerosis; Carotid Artery Diseases; Heart Diseases
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01
Hepatitis B
Details